Janus kinase 3: The controller and the controlled

Acta Biochimica et Biophysica Sinica

Volumn 44, Issue 3, 2012, Pages 187-196

  Wu, Wei ^a,b   Sun, Xiao Hong ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Asb2; JAK2; JAK3; Notch

Indexed keywords

CYTOKINE; JANUS KINASE 2; JANUS KINASE 3; NOTCH RECEPTOR;

ANIMAL; BIOLOGICAL MODEL; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMAN; IMMUNE SYSTEM; LYMPHOPOIESIS; METABOLISM; MOUSE; MOUSE MUTANT; PHENOTYPE; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINES; HUMANS; IMMUNE SYSTEM; JANUS KINASE 2; JANUS KINASE 3; LYMPHOPOIESIS; MICE; MICE, SCID; MODELS, BIOLOGICAL; PHENOTYPE; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84863296043     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmr105     Document Type: Review

References (98)

1. Pritchard MA, Baker E, Callen DF, Sutherland GR and Wilks AF. Two members of the JAK family of protein tyrosine kinases map to chromosomes 1p31.3 and 9p24. Mamm Genome 1992, 3: 36-38.
2. Firmbach-Kraft I, Byers M, Shows T, Dalla-Favera R and Krolewski JJ. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene 1990, 5: 1329-1336.
3. Riedy MC, Dutra AS, Blake TB, Modi W, Lal BK, Davis J and Bosse A, et al. Genomic sequence, organization, and chromosomal localization of human JAK3. Genomics 1996, 37: 57-61. (Pubitemid 26341834)
4. Rane SG and Reddy EP. JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells. Oncogene 1994, 9: 2415-2423. (Pubitemid 24228695)
5. Yamaoka K, Saharinen P, Pesu M, Holt VE, III, Silvennoinen O and O'Shea JJ. The Janus kinases (JAKs). Genome Biol 2004, 5: 253.
6. Feng J, Witthuhn BA, Matsuda T, Kohlhuber F, Kerr IM and Ihle JN. Activation of JAK2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol 1997, 17: 2497-2501. (Pubitemid 27175130)
7. Ungureanu D, Saharinen P, Junttila I, Hilton DJ and Silvennoinen O. Regulation of JAK2 through the ubiquitin-proteasome pathway involves phosphorylation of JAK2 on Y1007 and interaction with SOCS-1. Mol Cell Biol 2002, 22: 3316-3326. (Pubitemid 34453973)
8. Zhou YJ, Hanson EP, Chen YQ, Magnuson K, Chen M, Swann PG and Wange RL, et al. Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proc Natl Acad Sci USA 1997, 94: 13850-13855. (Pubitemid 28009673)
9. Luo H, Rose P, Barber D, Hanratty WP, Lee S, Roberts TM and Dearolf CR. Mutation in the JAK kinase JH2 domain hyperactivates Drosophila and mammalian JAK-Stat pathways. Mol Cell Biol 1997, 17: 1562-1571. (Pubitemid 27097386)
10. Saharinen P and Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of JAK2 and JAK3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002, 277: 47954-47963. (Pubitemid 36159324)
11. Chen M, Cheng A, Candotti F, Zhou YJ, Hymel A, Fasth A and Notarangelo LD, et al. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol 2000, 20: 947-956. (Pubitemid 30044232)
12. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C and Garçon L, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434: 1144-1148. (Pubitemid 40663494)
13. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR and Tichelli A, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352: 1779-1790. (Pubitemid 40570926)
14. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S and Vassiliou GS, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365: 1054-1061. (Pubitemid 40386783)
15. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ and Boggon TJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7: 387-397. (Pubitemid 40544655)
16. Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M and Goss VL, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006, 10: 65-75.
17. Cornejo MG, Kharas MG, Werneck MB, Le Bras S, Moore SA, Ball B and Beylot-Barry M, et al. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood 2009, 113: 2746-2754.
18. Candotti F, Oakes SA, Johnston JA, Giliani S, Schumacher RF, Mella P and Fiorini M, et al. Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood 1997, 90: 3996-4003. (Pubitemid 27484053)
19. Velazquez L, Mogensen KE, Barbieri G, Fellous M, Uze G and Pellegrini S. Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alpha/beta and for signal transduction. J Biol Chem 1995, 270: 3327-3334.
20. Yeh TC, Dondi E, Uze G and Pellegrini S. A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling. Proc Natl Acad Sci USA 2000, 97: 8991-8996. (Pubitemid 30626661)
21. Zhou YJ, Chen M, Cusack NA, Kimmel LH, Magnuson KS, Boyd JG and Lin W, et al. Unexpected effects of FERM domain mutations on catalytic activity of JAK3: structural implication for Janus kinases. Mol Cell 2001, 8: 959-969. (Pubitemid 34031799)
22. Elliott NE, Cleveland SM, Grann V, Janik J, Waldmann TA and Dave UP. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood 2011, 118: 3911-3921.
23. Chen M, Cheng A, Chen YQ, Hymel A, Hanson EP, Kimmel L and Minami Y, et al. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. Proc Natl Acad Sci USA 1997, 94: 6910-6915.
24. Haan S, Margue C, Engrand A, Rolvering C, Schmitz-Van de Leur H, Heinrich PC and Behrmann I, et al. Dual role of the JAK1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent JAK activation. J Immunol 2008, 180: 998-1007.
25. Funakoshi-Tago M, Pelletier S, Moritake H, Parganas E and Ihle JN. JAK2 FERM domain interaction with the erythropoietin receptor regulates JAK2 kinase activity. Mol Cell Biol 2008, 28: 1792-1801.
26. Radtke S, Haan S, Jorissen A, Hermanns HM, Diefenbach S, Smyczek T and Schmitz-Vandeleur H, et al. The JAK1 SH2 domain does not fulfill a classical SH2 function in JAK/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. J Biol Chem 2005, 280: 25760-25768. (Pubitemid 40962286)
27. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007, 178: 2623-2629. (Pubitemid 46333135)
28. Leonard WJ. Role of JAK kinases and STATs in cytokine signal transduction. Int J Hematol 2001, 73: 271-277. (Pubitemid 33758983)
29. Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J and Shiloh R, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010, 115: 1006-1017.
30. Shimoda K, Kato K, Aoki K, Matsuda T, Miyamoto A, Shibamori M and Numata A, et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000, 13: 561-571.
31. Karaghiosoff M, Neubauer H, Lassnig C, Kovarik P, Schindler H, Pircher H and McCoy B, et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000, 13: 549-560.
32. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J and Pflanz S, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002, 168: 5699-5708. (Pubitemid 34556153)
33. Shaw MH, Boyartchuk V, Wong S, Karaghiosoff M, Ragimbeau J, Pellegrini S and Muller M, et al. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci USA 2003, 100: 11594-11599. (Pubitemid 37205981)
34. Gurniak CB and Berg LJ. Murine JAK3 is preferentially expressed in hematopoietic tissues and lymphocyte precursor cells. Blood 1996, 87: 3151-3160. (Pubitemid 26115343)
35. O'Shea JJ. Targeting the JAK/STAT pathway for immunosuppression. Ann Rheum Dis 2004, 63(Suppl 2): ii67-ii71. (Pubitemid 39424662)
36. Alexander WS and Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004, 22: 503-529. (Pubitemid 38680432)
37. Kurzer JH, Argetsinger LS, Zhou YJ, Kouadio JL, O'Shea JJ and Carter-Su C. Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta. Mol Cell Biol 2004, 24: 4557-4570. (Pubitemid 44109138)
38. Cheng H, Ross JA, Frost JA and Kirken RA. Phosphorylation of human JAK3 at tyrosines 904 and 939 positively regulates its activity. Mol Cell Biol 2008, 28: 2271-2282. (Pubitemid 351429973)
39. Funakoshi-Tago M, Tago K, Kasahara T, Parganas E and Ihle JN. Negative regulation of JAK2 by its auto-phosphorylation at tyrosine 913 via the Epo signaling pathway. Cell Signal 2008, 20: 1995-2001.
40. Funakoshi-Tago M, Pelletier S, Matsuda T, Parganas E and Ihle JN. Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of JAK2. EMBO J 2006, 25: 4763-4772. (Pubitemid 44607022)
41. Ali S, Nouhi Z and Chughtai N. SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/degradation downstream of the prolactin receptor. J Biol Chem 2003, 278: 52021-52031. (Pubitemid 38035787)
42. Wu TR, Hong YK, Wang XD, Ling MY, Dragoi AM, Chung AS, Campbell AG and Carter-Su C. SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. J Biol Chem 2002, 277: 47572-47580. (Pubitemid 36159277)
43. Ishida-Takahashi R, Rosario F, Gong Y, Kopp K, Stancheva Z, Chen X and Carter-Su C. Phosphorylation of JAK2 on Ser(523) inhibits JAK2-dependent leptin receptor signaling. Mol Cell Biol 2006, 26: 4063-4073. (Pubitemid 43788010)
44. Mazurkiewicz-Munoz AM, Argetsinger LS, Kouadio JL, Stensballe A, Jensen ON, Cline JM and Carter-Su C. Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor. Mol Cell Biol 2006, 26: 4052-4062. (Pubitemid 43788009)
45. Yoshimura A, Naka T and Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007, 7: 454-465. (Pubitemid 46834848)
46. Johnston JA and O'Shea JJ. Matching SOCS with function. Nat Immunol 2003, 4: 507-509. (Pubitemid 36701330)
47. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K and Matsumoto A, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997, 387: 921-924. (Pubitemid 27289595)
48. Babon JJ, Sabo JK, Soetopo A, Yao S, Bailey MF, Zhang JG and Nicola NA, et al. The SOCS box domain of SOCS3: structure and interaction with the elonginBC-cullin5 ubiquitin ligase. J Mol Biol 2008, 381: 928-940.
49. Babon JJ, Sabo JK, Zhang JG, Nicola NA and Norton RS. The SOCS box encodes a hierarchy of affinities for Cullin5: implications for ubiquitin ligase formation and cytokine signalling suppression. J Mol Biol 2009, 387: 162-174.
50. Kamizono S, Hanada T, Yasukawa H, Minoguchi S, Kato R, Minoguchi M and Hattori K, et al. The SOCS box of SOCS-1 accelerates ubiquitindependent proteolysis of TEL-JAK2. J Biol Chem 2001, 276: 12530-12538.
51. Waiboci LW, Ahmed CM, Mujtaba MG, Flowers LO, Martin JP, Haider MI and Johnson HM. Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist. J Immunol 2007, 178: 5058-5068. (Pubitemid 46595289)
52. Giordanetto F and Kroemer RT. A three-dimensional model of suppressor of cytokine signalling 1 (SOCS-1). Protein Eng 2003, 16: 115-124. (Pubitemid 36458650)
53. Thomis DC and Berg LJ. Peripheral expression of JAK3 is required to maintain T lymphocyte function. J Exp Med 1997, 185: 197-206.
54. Baird AM, Lucas JA and Berg LJ. A profound deficiency in thymic progenitor cells in mice lacking JAK3. J Immunol 2000, 165: 3680-3688. (Pubitemid 32057273)
55. Park SY, Saijo K, Takahashi T, Osawa M, Arase H, Hirayama N and Miyake K, et al. Developmental defects of lymphoid cells in JAK3 kinasedeficient mice. Immunity 1995, 3: 771-782. (Pubitemid 26091150)
56. Saijo K, Park SY, Ishida Y, Arase H and Saito T. Crucial role of JAK3 in negative selection of self-reactive T cells. J Exp Med 1997, 185: 351-356. (Pubitemid 27078291)
57. Thomis DC, Lee W and Berg LJ. T cells from JAK3-deficient mice have intact TCR signaling, but increased apoptosis. J Immunol 1997, 159: 4708-4719. (Pubitemid 127471005)
58. Mayack SR and Berg LJ. Cutting edge: an alternative pathway of CD4 + T cell differentiation is induced following activation in the absence of gamma-chain-dependent cytokine signals. J Immunol 2006, 176: 2059-2063. (Pubitemid 43201650)
59. Seki Y, Hayashi K, Matsumoto A, Seki N, Tsukada J, Ransom J and Naka T, et al. Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proc Natl Acad Sci USA 2002, 99: 13003-13008.
60. Yagi R, Zhu J and Paul WE. An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation. Int Immunol 2011, 23: 415-420.
61. Shi M, Lin TH, Appell KC and Berg LJ. Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation. Immunity 2008, 28: 763-773. (Pubitemid 351778407)
62. Suzuki K, Nakajima H, Saito Y, Saito T, Leonard WJ and Iwamoto I. Janus kinase 3 (JAK3) is essential for common cytokine receptor gamma chain (gamma(c))-dependent signaling: comparative analysis of gamma(c), JAK3, and gamma(c) and JAK3 double-deficient mice. Int Immunol 2000, 12: 123-132. (Pubitemid 30088304)
63. Yao Z, Cui Y, Watford WT, Bream JH, Yamaoka K, Hissong BD and Li D, et al. Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci USA 2006, 103: 1000-1005. (Pubitemid 43212211)
64. Cornejo MG, Boggon TJ and Mercher T. JAK3: a two-faced player in hematological disorders. Int J Biochem Cell Biol 2009, 41: 2376-2379.
65. Nie L, Perry SS, Zhao Y, Huang J, Kincade PW, Farrar MA and Sun XH. Regulation of lymphocyte development by cell-type-specific interpretation of Notch signals. Mol Cell Biol 2008, 28: 2078-2090. (Pubitemid 351342637)
66. Wilson A, MacDonald HR and Radtke F. Notch 1-deficient common lymphoid precursors adopt a B cell fate in the thymus. J Exp Med 2001, 194: 1003-1012. (Pubitemid 32953268)
67. Radtke F, Wilson A, Stark G, Bauer M, van Meerwijk J, MacDonald HR and Aguet M. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 1999, 10: 547-558. (Pubitemid 29262657)
68. Pui JC, Allman D, Xu L, DeRocco S, Karnell FG, Bakkour S and Lee JY, et al. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 1999, 11: 299-308. (Pubitemid 29463238)
69. Nie L, Xu M, Vladimirova A and Sun XH. Notch-induced E2A ubiquitination and degradation are controlled by MAP kinase activities. EMBO J 2003, 22: 5780-5792. (Pubitemid 37408817)
70. Nie L, Zhao Y, Wu W, Yang YZ, Wang HC and Sun XH. Notch-induced Asb2 expression promotes protein ubiquitination by forming non-canonical E3 ligase complexes. Cell Res 2011, 21: 754-769.
71. Harper JW. Protein destruction: adapting roles for Cks proteins. Curr Biol 2001, 11: R431-R435. (Pubitemid 32532801)
72. Jackson PK and Eldridge AG. The SCF ubiquitin ligase: an extended look. Mol Cell 2002, 9: 923-925. (Pubitemid 34626661)
73. Bergamin E, Wu J and Hubbard SR. Structural basis for phosphotyrosine recognition by suppressor of cytokine signaling-3. Structure 2006, 14: 1285-1292. (Pubitemid 44176372)
74. Wu W and Sun XH. A mechanism underlying notch-induced and ubiquitin-mediated JAK3 degradation. J Biol Chem 2011 October 3 doi: 10.1074/jbc.M111.273755.
75. Sarmento LM, Huang H, Limon A, Gordon W, Fernandes J, Tavares MJ and Miele L, et al. Notch1 modulates timing of G1-S progression by inducing SKP2 transcription and p27 Kip1 degradation. J Exp Med 2005, 202: 157-168. (Pubitemid 41002918)
76. Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS and McBride OW, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993, 73: 147-157. (Pubitemid 23115456)
77. Noguchi M, Nakamura Y, Russell SM, Ziegler SF, Tsang M, Cao X and Leonard WJ. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science 1993, 262: 1877-1880. (Pubitemid 24041859)
78. Kondo M, Takeshita T, Higuchi M, Nakamura M, Sudo T, Nishikawa S and Sugamura K. Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes. Science 1994, 263: 1453-1454. (Pubitemid 24137837)
79. Kondo M, Takeshita T, Ishii N, Nakamura M, Watanabe S, Arai K and Sugamura K. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science 1993, 262: 1874-1877. (Pubitemid 24041858)
80. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F and Ugazio AG, et al. Mutations of JAK-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995, 377: 65-68.
81. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ and Migone TS, et al. Mutation of JAK3 in a patient with SCID: essential role of JAK3 in lymphoid development. Science 1995, 270: 797-800.
82. Narla RK, Liu XP, Myers DE and Uckun FM. 4-(30-Bromo-40hydroxylphenyl)- amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. Clin Cancer Res 1998, 4: 1405-1414. (Pubitemid 28265222)
83. Sudbeck EA, Liu XP, Narla RK, Mahajan S, Ghosh S, Mao C and Uckun FM. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res. 1999, 5: 1569-1582. (Pubitemid 29282966)
84. Podder H and Kahan BD. Janus kinase 3: a novel target for selective transplant immunosupression. Expert Opin Ther Targets 2004, 8: 613-629. (Pubitemid 40028370)
85. Changelian PS, Moshinsky D, Kuhn CF, Flanagan ME, Munchhof MJ, Harris TM and Whipple DA, et al. The specificity of JAK3 kinase inhibitors. Blood 2008, 111: 2155-2157. (Pubitemid 351451528)
86. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT and Chan KW, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008, 26: 127-132.
87. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH and Rizzuti BJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003, 302: 875-888.
88. Kudlacz E, Perry B, Sawyer P, Conklyn M, McCurdy S, Brissette W and Flanagan And M, et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 2004, 4: 51-57. (Pubitemid 38155489)
89. Conklyn M, Andresen C, Changelian P and Kudlacz E. The JAK3 inhibitor CP-690550 selectively reduces NK and CD8 + cell numbers in cynomolgus monkey blood following chronic oral dosing. J Leukoc Biol 2004, 76: 1248-1255. (Pubitemid 39602962)
90. Borie DC, Changelian PS, Larson MJ, Si MS, Paniagua R, Higgins JP and Campbell A, et al. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation 2005, 79: 791-801. (Pubitemid 40546198)
91. Paniagua R, Si MS, Flores MG, Rousvoal G, Zhang S, Aalami O and Campbell A, et al. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation 2005, 80: 1283-1292. (Pubitemid 41746807)
92. Wojciechowski D and Vincenti F. Targeting JAK3 in kidney transplantation: current status and future options. Curr Opin Organ Transplant 2011, 16: 614-619.
93. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G and O'Shea JJ. Therapeutic targeting of Janus kinases. Immunol Rev 2008, 223: 132-142. (Pubitemid 351986189)
94. Milici AJ, Kudlacz EM, Audoly L, Zwillich S and Changelian P. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 2008, 10: R14.
95. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S and Connell CA, et al. Phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to DMARDs. Arthritis Rheum 2011, doi: 10.1002/art.33383.
96. Tak PP and Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 2011, 13(Suppl 1): S5.
97. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S and Zwillich SH. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011, 63: 1150-1158.
98. Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S and van De Walle I, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 2011, 473: 230-233.